Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724178 | 0.88 | GRM5 (0.37) | KMT2AMEN1KDM4ERXFP1SMYD3 | |
| SCHEMBL990840 | 0.87 | GRM5 (0.60) | KMT2AMEN1GRM5L3MBTL1NPC1 | |
| SCHEMBL990817 | 0.87 | GRM5 (0.60) | KMT2AMEN1GRM5L3MBTL1NPC1 | |
| SCHEMBL3284072 | 0.86 | GRM5 (0.57) | GRM5L3MBTL1NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL990125 | 0.86 | GRM5 (0.57) | GRM5L3MBTL1NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL990340 | 0.86 | L3MBTL1 (0.59) | KMT2AMEN1GRM5L3MBTL1NPC1 | |
| SCHEMBL989485 | 0.84 | GRM5 (0.47) | GRM5L3MBTL1NPC1ALDH1A1RAB9A | |
| SCHEMBL990851 | 0.84 | GRM5 (0.46) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL2818567 | 0.83 | L3MBTL1 (0.47) | KMT2AMEN1GRM5L3MBTL1NPC1 | |
| SCHEMBL990869 | 0.82 | GRM5 (0.48) | KMT2AMEN1GRM5L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | claimed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | claimed |
| US-20150272929-A1 | ORGANIC COMPOUNDS | UMBRICHT DANIEL (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20140194423-A1 | COMBINATION PRODUCTS | GOMEZ-MANCILLA BALTAZAR (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703809-B2 | Combination products | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120122878-A1 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-1877365-B1 | ACETYLENE DERIVATIVES | NOVARTIS AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20100249136-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| WO-2010000763-A2 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2010-01-07 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | KMT2A 2216/4885MEN1 732/4885KDM4E 3641/4885 |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | KMT2A 1101/4885MEN1 4664/4885KDM4E 1396/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | KMT2A 1058/4885MEN1 4674/4885KDM4E 1443/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | KMT2A 1058/4885MEN1 4674/4885KDM4E 1443/4885 |
| US-20120122878-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | KMT2A 278/4885MEN1 4721/4885KDM4E 318/4885 |
| US-20150272929-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | KMT2A 1731/4885MEN1 4778/4885KDM4E 1141/4885 |
| US-20140194423-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | KMT2A 278/4885MEN1 4721/4885KDM4E 318/4885 |
| US-20100249136-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | KMT2A 1731/4885MEN1 4778/4885KDM4E 1141/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | KMT2A 2216/4885MEN1 732/4885KDM4E 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.